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Staphylococcus aureus is a proficient biofilm former on host tissues and medical implants. We mutagenized
S. aureus strain SH1000 to identify loci essential for ica-independent mechanisms of biofilm maturation and
identified multiple insertions in the rsbUVW-sigB operon. Following construction and characterization of a sigB
deletion, we determined that the biofilm phenotype was due to a lack of sigma factor B (SigB) activity. The
phenotype was conserved in a sigB mutant of USA300 strain LAC, a well-studied community-associated
methicillin-resistant S. aureus isolate. We determined that agr RNAIII levels were elevated in the sigB mutants,
and high levels of RNAIII expression are known to have antibiofilm effects. By introducing an agrmutation into
the SH1000 or LAC sigB deletion strain, S. aureus regained biofilm capacity, indicating that the biofilm
phenotype was agr dependent. Protease activity is linked to agr activity and ica-independent biofilm formation,
and we observed that the protease inhibitors phenylmethylsulfonyl fluoride and -macroglobulin could reverse
the sigB biofilm defect. Similarly, inactivating genes encoding both the aureolysin and Spl extracellular
proteases in the sigB mutant restored biofilm capacity. Due to the growing link between murein hydrolase
activity and biofilm maturation, autolysin zymography was performed, which revealed an altered profile in the
sigBmutant; again, the phenotype could be repaired through protease inactivation. These findings indicate that
the lack of SigB activity results in increased RNAIII expression, thus elevating extracellular protease levels and
altering the murein hydrolase activity profile. Altogether, our observations demonstrate that SigB is an
essential regulator of S. aureus biofilm maturation.
Staphylococcus aureus is the causative agent of a diverse
array of acute and chronic infections (48). The ability of S.
aureus to attach to surfaces and form a biofilm is a critical
determinant of the course of chronic disease (16). The colo-
nized surfaces can be medical implants, such as catheters and
orthopedic implants (15), or host tissue, as exemplified by
osteomyelitis and infective endocarditis (12, 58). The challenge
presented by biofilms is their remarkable resistance to both
host defenses and antimicrobial therapies, limiting available
treatment options (21).
In recent studies, it has become clear that there are at least
two mechanisms of biofilm development in S. aureus (54). One
mechanism requires the production of an extracellular poly-
saccharide, termed polysaccharide intercellular adhesin (PIA),
or polymeric N-acetyl-glucosamine. The ica gene cluster is
required for the production of PIA, and this locus is essential
for biofilm formation in PIA-producing strains (17, 68). Later
studies determined that mutations in the ica locus in multiple
S. aureus strains do not impair biofilm capacity (6, 11, 19),
revealing a second, ica-independent mechanism of biofilm for-
mation. Examination of methicillin-resistant S. aureus (MRSA)
strains indicates that these isolates predominantly form the
ica-independent biofilms (24, 55), suggesting that there is a
need to decipher mechanisms of biofilm maturation and dis-
persal in the absence of PIA.
Some of the best-studied factors involved in the ica-inde-
pendent biofilm processes are the agr and sarA global reg-
ulatory systems. Both regulators are known to modulate
attachment to surfaces but in opposing manners, with SarA
being essential for attachment and the agr system control-
ling the dispersal mechanism (5, 11, 70, 75). Other global
regulators, such as the two-component autolysis-related lo-
cus ArlRS, have also been implicated in ica-independent
biofilms (67). Additionally, surface adhesins, such as the
biofilm adhesin protein (Bap) and the SasG adhesin (Aap in
Staphylococcus epidermidis), are required for the ica-inde-
pendent mechanism (14, 18, 19, 62). Proteolytic processing of
the SasG adhesin is necessary for attachment (14, 62), and re-
cently we demonstrated that extracellular proteases have an ad-
ditional role in the dispersal from ica-independent biofilms (11),
further outlining the complex nature of biofilm maturation and
dispersal in the absence of PIA.
Based on the emerging importance of ica-independent
biofilms, we have initiated a screen for chromosomal loci
essential for biofilm formation. In preliminary tests, we
identified multiple transposon insertions in the rsbUVW-sigB
operon. The result of these insertions was a defect in SigB
activity, a known global regulator induced in stationary
phase and by a variety of environmental stresses, including
heat, alkaline, and high-salt conditions (57). Although SigB-
defective strains are reported to form biofilms (70), we ob-
served a pronounced biofilm phenotype in sigB mutants using
both a methicillin-susceptible strain and a community-associ-
ated MRSA (CA-MRSA) USA300 isolate. The characteriza-
tion of the SigB role in biofilm maturation is the focus of this
report.
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MATERIALS AND METHODS
Strains and growth conditions. The bacterial strains used in this study are
described in Table 1. Strains of Escherichia coli were grown in Luria-Bertani
broth or Luria agar plates, and growth medium was supplemented with ampi-
cillin (100 g/ml) as needed for maintenance of plasmids. Strains of S. aureus
were grown in tryptic soy broth (TSB) or tryptic soy agar (TSA). For selection of
chromosomal markers or maintenance of plasmids, S. aureus antibiotic concen-
trations were (in g/ml) the following: chloramphenicol (Cam), 10; erythromycin
(Erm), 10; kanamycin (Kan), 20; and tetracycline (Tet), 5. All reagents were
purchased from Fisher Scientific (Pittsburg, PA) and Sigma (St. Louis, MO)
unless otherwise indicated.
Recombinant DNA and genetic techniques. Restriction and modification en-
zymes were purchased from New England Biolabs (Beverly, MA) and were used
according to the manufacturer’s instructions. All DNA manipulations were per-
formed in E. coli strain DH5-E (Invitrogen, Carlsbad, CA) or strain BW25141
(20). All oligonucleotides were synthesized at Integrated DNA Technologies
(Coralville, IA). Plasmids were transformed into S. aureus RN4220 by electro-
poration as described previously (63). Plasmids were moved from strain RN4220
to other strains using transduction by bacteriophage 80 as described previ-
ously (53). In some cases, chromosomal markers were also moved by bacte-
riophage 80 transduction between S. aureus strains. Nonradioactive se-
quencing was performed at the DNA sequencing facility at the University of
Iowa.
Generation of transposon insertions. A plasmid for generating Tn5 insertions in
S. aureus was generated using the plasmid pKOR1 (3) as a template. The hyper-
mutable Tn5 transposase gene from plasmid pGRTYB35 (7) was amplified using the
oligonucleotides ARH87 (5-GTTGTTGGTACCTTTCCCGGGAATAATTTTGT
TTAACTTTAAGAAGGAG-3) and ARH88 (5-GTTGTTGGGCCCTTTAGAT
CTTTTCGTACGTCATATCTTGATCCCCTGCGCC-3). The PCR product was
digested with KpnI and ApaI and ligated into plasmid pKOR1 cut with the same
enzymes. This cloning step removed the Gateway region and placed the transposase
gene immediately downstream of the Cam resistance gene on pKOR1. Using the
BsiWI and BglII restriction sites encoded within oligonucleotide ARH88, a fragment
containing the Tn5 mosaic ends and a Kan resistance determinant was cloned onto
the plasmid. The mosaic ends were constructed using the oligonucleotides described
by Goryshin et al. (28), which flanked a Kan resistance gene from pDG783 (30). The
final plasmid was named pTN11 and was used for the initial Tn5 hopping experi-
ments. For Tn5mutagenesis, plasmid pTN11 was transformed into S. aureus SH1000
and maintained at 30°C on TSA supplemented with Cam. Individual colonies were
picked and grown to an optical density at 600 nM (OD600) of 0.4, and dilutions were
plated on TSA supplemented with Kan and anhydrotetracycline (400 ng/ml). Plates
were incubated at 42°C, and colonies were tested for Cam sensitivity.
For mariner mutagenesis, SH1000 was transformed with plasmids pFA545 and
pBursa, and mutagenesis was performed as described previously (2). Mutants
were banked in deep-well microtiter titer plates in TSB with 10% glycerol and
stored at 80°C. Biofilm and protease phenotypes of the banked mutants were
tested in parallel. The biofilm capacity of transposon mutants in microtiter plates
was measured as described previously (11). Qualitative protease activity was
assessed by testing 48 mutants per plate on milk agar and estimating zones of
clearing (37). Transposon insertions described in this report were reconstructed
into parent strain SH1000 using bacteriophage 80, and protease and biofilm
assays were repeated.
TABLE 1. Strains and plasmids
Strain or plasmid Description or genotype Resistancemarker(s)
Source or
reference
Strains
E. coli strains
DH5-E Cloning strain None Invitrogen
BW25141 Cloning strain None 20
S. epidermidis ATCC R97-03
PIA control strain None 65
S. aureus strains
LAC CA-MRSA USA300-0114 Erm, Tet 72
MN8 Toxic shock isolate None 50
MN8m PIA overproducer None 50
MN8ica ica::tet Tet 50
RN4220 Restriction modification deficient None 45
SH1000 sigB derivative of NCTC8325-4 None 33
SH1001 SH1000 agr::tetM Tet 33
SH1002 SH1000 sarA::kan Kan 33
AH528 SH1000 rsbU::Tn5 Kan This work
AH595 SH1000 ica::tet Tet 11
AH750 SH1000 aur spl::Erm Erm 11
AH1012 SH1000 sigB None This work
AH1096 LAC sigB Erm This work
AH1106 SH1000 sigB agr::tetM Tet This work
AH1136 SH1000 sigB aur spl::Erm Erm This work
AH1203 LAC agr::tetM Erm, Tet This work
AH1204 LAC sigB agr::tetM Erm, Tet This work
AH1308 LAC ica::tet Tet This work
Plasmids
pAH1 P3agr-mCherry Cam This work
pAH6 Pasp23-mCherry Cam This work
pAH8 P3agr-mCherry Erm This work
pAH12 Pasp23-mCherry Erm This work
pALC2073 Shuttle vector with tet promoter Cam 4
pALC2084 Tet-inducible GFP Cam 4
pALC2109 sigB gene cloned into pALC2073 Cam 4
pBursa Mariner hopping plasmid Cam, Erm 2
pDB59 P3agr-YFP Cam 75
pFA545 Mariner transposase Tet 2
pKOR1 Gene replacement plasmid Cam 3
pTN11 Tn5 hopping plasmid Cam, Kan This work
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Mapping transposon insertions. Transposon insertion sites were mapped us-
ing a modification of an arbitrary PCR technique (40). Briefly, amplification was
performed using Phusion DNA Polymerase (New England Biolabs) in an MJ
Mini thermocycler (Bio-Rad) on chromosomal DNA prepared with a Puregene
DNA purification kit (Gentra Systems). Two rounds of PCR were performed.
The first round consisted of the following program: 5 cycles of 98°C for 10 s, 30°C
for 20 s, and 72°C for 45 s, followed by 30 cycles of 98°C for 10 s, 40°C for 20 s,
and 72°C for 45 s, with a final elongation step of 72°C for 10 min. Oligonucle-
otides for mapping the Tn5 insertion were TN11-For2 (5-GAGCTATTTTTT
GACTTACTGGGG-3) for the 5 end and TN11-Rev2 (5-GGTCCAATTCTC
GTTTTCATAC-3) for the 3 end of Tn11 in conjunction with an arbitrary
primer (Arb1, 5-GGCCACGCGTCGACTAGTACNNNNNNNNNNGATAT-
3). The second round of amplification was performed with the following param-
eters: 30 cycles of 98°C for 10 s, 50°C for 20 s, and 72°C for 45 s, followed by
elongation at 72° for 10 min. Oligonucleotides for the second round were TN11-
For1 (5-GGATGAATTGTTTTAGTACCTAGATTTAG-3) for the 5 end and
TN11-Rev1 (5-CCTATCACCTCAACAATTGAAGCTT-3) for the 3 end in
conjunction with an arbitrary primer (Arb2, 5-GGCCACGCGTCGACTAGTA
C-3). For mapping mariner transposon insertions, the oligonucleotides were
changed. For the first round of amplification, the Tn5 oligonucleotides were
swapped with the mariner 5 end (TnMarRev1, 5-GTAAATCAAGTACCAA
AATCCG-3) or 3 end (TnMarFor1, 5-TCCGTATGTTGCATCACCTTCAC-
3), and for the second round, the mariner oligonucleotides were TnMarRev2
(5-AGTTCCTATATAGTTATACGCGTCTAG-3) for the 5 end or TnMarFor2
(5-GTGCCCATTAACATCACCATCTA-3) for the 3 end.
Construction of a sigB deletion. Chromosomal deletions of sigB were con-
structed in SH1000 using the pKOR1 plasmid for allelic replacement as de-
scribed by Bae and Schneewind (3). Briefly, flanking regions of sigB were am-
plified using primers SigBupf (5-GGGGACAAGTTTGTACAAAAAAGCAG
GCTCTTAATATAGAAACAACCACTCAAG-3), SigBupc (5-ACGCGTGG
TACCGCTAGCCATTATTTCGCACCTGCTCTTTTTTTAT-3), SigBdownc
(5-AAATGAGCTAGCGGTACCACGCGTTAGAATTTGTTTATTAATGA
TACG-3), and SigBdownf (5-GGGGACCACTTTGTACAAGAAAGCTGGG
TGTCTTTTTCTTTTGTTTAAAAGGCC-3). The two PCR products were
joined with overlap extension (69) and moved into pKOR1 using the Gateway
cloning system (Invitrogen). The resulting plasmid was verified and transformed
into SH1000, and the sigB deletion was constructed as described previously (3).
The sigB deletion in strain LAC was constructed using the same plasmid and
protocol.
Construction of reporter plasmids. (i) pAH1 and pAH6 construction. The
asp23 promoter was amplified from S. aureus SH1000 genomic template using
the oligonucleotides Asp-Bam (5-GTTGTTGGATCCTAGCGTTTCTATTAA
TCGCGATATTATTC-3) and Asp2 (5-GTTGTTGGTACCAATAGATTCTC
CTTTTACTTGTTAATTTTTATA-3). A second PCR was performed using
plasmid pDB59 as a template with the oligonucleotides AspYFP (5-GGAGA
ATCTATTGGTACCAACAACAAGAAGGAGATATACATATGAGTAAAG
G-3; YFP is yellow fluorescent protein) and YFP EcoRI (5-GTTGTTGAAT
TCTTATTTGTATAGTTCATCCATGCCA-3). The two PCR products were
fused with overlap extension PCR (69), digested with BamHI and EcoRI, and
ligated into pDB59 digested by the same enzymes, resulting in plasmid pAH5. To
change fluorescent reporters, the mCherry gene was removed from pAH9 (10)
using KpnI and EcoRI and ligated into pAH5 cut with the same enzymes. The
resulting plasmid, called pAH6, has the asp23 promoter driving the mCherry
reporter. To build pAH1, the agr P3 promoter region was PCR amplified from
SH1000 genomic DNA with oligonucleotides incorporating HindIII and KpnI
sites (for, 5-GTTGTTAAGCTTCTGTCATTATACGATTTAGTACAATC-3;
rev, 5-GTTGTTGGTACCTTAAACAACTCATCAACTATTTTCC-3). The
PCR product was cloned into the vector pCR2.1 using a TOPO-TA cloning kit
(Invitrogen) according to manufacturer’s instructions, generating an intermedi-
ate plasmid called pCR2.1-RNAIII. The promoter fragment was removed from
this plasmid with BamHI and KpnI and ligated into pAH6 digested with the same
enzymes. The resulting plasmid, called pAH1, has the agr P3 promoter driving
the mCherry reporter.
(ii) pAH8 and pAH12 construction. A DNA fragment containing the agr P3
promoter was removed from the pCR2.1-RNAIII clone (described above) with
HindIII and KpnI, and this fragment was cloned into pAH9 (10) cut with the
same enzymes. The resulting vector, called pAH8, has the agr P3 promoter
driving the mCherry reporter in an Erm-resistant plasmid. For pAH12, the asp23
promoter was PCR amplified with oligonucleotides Asp1 (5-GGGAAAAAGC
TTTAGCGTTTCTATTAATCGCGATATTATTC-3) and Asp2 (described
above) and cloned into the vector pCR2.1 using a TOPO-TA cloning kit (In-
vitrogen). The promoter fragment was removed with HindIII and KpnI and
cloned into pAH9 cut with the same enzymes. The resulting plasmid, called
pAH12, has the asp23 promoter driving mCherry reporter in an Erm-resistant
plasmid.
Hemolysis assays. Qualitative hemolysis was monitored using sheep blood
agar for -toxin or rabbit blood agar plates for -toxin. Quantitative measure-
ments of hemolysis were performed using rabbit blood cell fractions (modified
from Jiang et al.) (35). Briefly, blood was pelleted at 8,000 rpm for 10 min in a
microcentrifuge tube. Cells were resuspended in 25 volume of RPMI 1640
medium (Invitrogen). For S. aureus samples, strains were grown for 20 h in TSB,
and cells were removed by centrifugation and passage through a 0.2-m-pore-
size cutoff filter (Amicon). Hemolytic titers were performed by gently mixing 500
l of supernatant with 500 l of blood cell dilutions and incubating samples for
15 min at 37°C. As a reference, total hemolysis was accomplished using 0.2%
sodium dodecyl sulfate (SDS). Samples were then centrifuged at 8,000 rpm for 10
min to remove unlysed cells. Release of hemoglobin was measured by monitoring
the absorbance at 540 nm. Hemolytic titers were defined as the dilution factor of
supernatant required to lyse half of the red blood cells.
Protease assays. Quantitative protease activity measurements were deter-
mined using Azocoll (Calbiochem) reagent as described previously (26).
Carotenoid production. The carotenoid staphyloxanthin was extracted with
methanol from S. aureus strains (47). Briefly, strains were grown on TSA plates
at 37°C for 24 and 48 h. Cells were harvested in sterile water and adjusted to an
OD600 of 10. One milliliter was pelleted and resuspended in 1 ml of 100%
methanol, and the mixture was vortexed vigorously for 5 min. Cell debris was
removed by centrifugation, and a spectral scan was performed using a Beckman
DU 7500 spectrophotometer. The absorbance of peaks at 450- and 470-nm
wavelengths was evaluated.
Real-time PCR. S. aureus strains were grown in TSB and harvested during
stationary phase growth. Levels of RNAIII transcript were determined using
quantitative real-time reverse transcription-PCR (qRT-PCR) as described pre-
viously (43). RNAIII transcript was amplified using primers RNAIIIfor (5-AG
TCACCGATTGTTGAAATGATATCT-3) and RNAIIIrev (5AGGAAGGAG
TGATTTCAATGGC-3). As a control, 16S mRNA was amplified as described
previously (43).
PIA production. Levels of PIA production were measured using quantitative
dot blot analysis based on a modified version of a protocol reported by Cramton
et al. (17). Cells were collected from overnight cultures of S. aureus strains grown
in 66% TSB with 0.2% glucose. A standard number of cells (5  109) was
collected by centrifugation and resuspended in 200 l of 0.5 M EDTA, pH 8.
Samples were boiled for 5 min, and then cell debris was cleared by centrifugation
at 13,000 rpm for 15 min. After preparation, 5 l of the sample was applied to
a 0.45-m-pore-size nitrocellulose membrane (Whatman) that was prewashed in
sterile water. The membrane was blocked for 1 h in 5% milk before primary
antibody was applied (rabbit-anti-PIA at 1:20,000; kindly provided by Paul Fey)
and incubated for 1 h. The secondary antibody of horseradish peroxidase-con-
jugated goat-anti-rabbit antibody (Upstate) was applied for 1 h. Detection was
performed using SuperSignal West Pico chemiluminescent substrate (Pierce)
according to the manufacturer’s specifications and an LAS-1000 luminescent
imager from Fuji (Standford, CT) with ImageReader software (Fuji). Quantifi-
cation was performed using ImageGauge software (Fuji).
Biofilm assays. Microtiter plate biofilms and flow cell biofilms were grown as
described previously (11). For culture media, microtiter biofilms were grown in
66% TSB supplemented with 0.2% glucose, and flow cell biofilms were grown in
2% TSB supplemented with 0.2% glucose. For protease inhibition in microtiter
biofilms, cells were added to the plate with phenylmethylsulfonyl fluoride
([PMSF] dissolved in 2% dimethyl sulfoxide [DMSO] at a final concentration of
400 M) or 2-macroglobulin (final concentration, 0.25 units/ml; Roche). Con-
focal fluorescence laser microscopy (CLSM) was performed using a Nikon
Eclipse E600 microscope with a Radiance 2100 system (Bio-Rad). CSLM and
image analysis were performed as described previously (11). For in situ moni-
toring of biofilm growth using CSLM, S. aureus strains were transformed with the
pALC2084 plasmid, which encodes a green fluorescent protein (GFP) reporter
under the control of a Tet-inducible promoter (4). For plasmid maintenance and
GFP expression, flow cell growth medium was supplemented with 1 g/ml Cam
and 20 ng/ml anhydrotetracycline. For biofilm poststaining, biofilms were treated
with 330 nM Syto9 (LIVE/DEAD BacLight Bacterial Viability Kit; Molecular
Probes) 15 min prior to visualization.
Protease and autolysin zymography. S. aureus overnight cultures containing
the appropriate plasmid were inoculated into 20 ml of TSB medium supple-
mented with Cam. For sigB mutant complementation, 50 ng/l anhydrotetracy-
cline was added to induce gene expression. Cultures were grown at 37°C with
shaking to an OD600 of 1.0. Cells were pelleted by centrifugation and removed by
filtration using a 0.20-m-pore-size syringe filter. Extracellular protease zymog-
raphy was performed as described previously (46). Briefly, supernatants were
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concentrated 100-fold (15 ml to 0.15 ml) with a Centricon 3 concentrator (Mil-
lipore, Billerica, MA) at 4°C according to the manufacturer’s instructions. Con-
centrated supernatants were mixed with an equal volume of Laemmli sample
buffer, and 20 l was separated by 8% SDS-polyacrylamide gel electrophoresis
(PAGE). Gels were supplemented with 0.2% gelatin (wt/vol) as a protease
substrate. To remove SDS following electrophoresis, gels were washed succes-
sively with 50-ml portions of 2.5% (vol/vol) Triton X-100 in distilled water (two
times for 10 min each time), 2.5% Triton X-100 in Tris buffer (50 mM Tris-HCl,
pH 7.4) (two times for 10 min each time), and Tris buffer (two times for 10 min
each time). After gels were washed, they were placed in 50 ml of Tris buffer and
incubated at 37°C for 15 h. For visualization of protease clearing zones, gels were
stained with Coomassie brilliant blue. Autolysin (murein hydrolase) zymography
was performed as described previously (42). Cell cultures were grown, and
supernatants were prepared and concentrated as described above. Samples were
separated on 8% SDS-PAGE gels supplemented with 0.2% Micrococcus luteus
cells (wt/vol) as a substrate. SDS was removed as described above, and autolysin
activity was visualized with staining using 1% methylene blue in 0.01% KOH,
followed by destaining in deionized water.
RESULTS
Isolation of transposon insertions in the rsbU gene. To gain
insight on loci involved in biofilm formation, we utilized a new
Tn5 transposon system to mutagenize S. aureus strain SH1000.
In preliminary tests, several hundred insertions were isolated
to verify the activity of the Tn5 system and begin assessment of
biofilm capacity. Through pilot tests for biofilm growth in mi-
crotiter plates, one of the Tn5 mutants, AH528, was com-
pletely defective in biofilm formation (Fig. 1A). Using arbi-
trary PCR, the insertion was mapped to the rsbU gene (Fig.
1B), encoding a positive regulator of the alternative sigma
factor B (SigB). Based on this finding, we began to investigate
the role of the SigB system in biofilm formation, which is the
focus of the studies described in this report. Unfortunately,
through our continued testing of the mutagenesis system, we
observed that many of the other isolated Tn5 insertions were
siblings. Despite repeated attempts, the problem was not cor-
rected, and we speculate that this is due in part to the unreg-
ulated, background expression of the transposase gene, result-
ing in premature hopping. As an alternative, we began using
the bursa aurealis (mariner) mutagenesis system developed by
Bae et al. (2), and the sibling issue was not observed using this
system.
In our preliminary screening of 	3,500 mariner transposon
mutants, we identified two additional insertions that visually
matched the agar plate phenotypes of the rsbU::Tn5 mutant
(data not shown). The phenotypes are striking and easily iden-
tifiable, highlighted by a lack of carotenoid, hyperprotease
production, and hyperhemolysis (see below), and they are con-
sistent with previous reports of mutations in the rsbUVW-sigB
locus (56). One of the mariner insertions mapped to rsbU,
approximately 600 bp downstream of the Tn5 insertion, and
the second mariner insertion mapped to the rsbV gene (Fig.
1B), the anti-anti-SigB factor. Importantly, the rsbU and rsbV
FIG. 1. Biofilm phenotypes of transposon insertions in the rsbUVW-sigB locus. (A) Microtiter biofilm assays of the wild-type (SH1000), three
transposon mutants in rsbUV genes, and constructed sigB and sigB agr mutants. The sarA::Kan mutant was included as a negative control. The
crystal violet in each well was solubilized and the OD595 was determined. (B) Graphic map of approximate locations of transposon insertions in
the rsbUVW-sigB locus.
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mariner insertions were also defective in biofilm formation
(Fig. 1A). We are in the process of scaling up the mariner
screen for a more complete analysis of the S. aureus loci re-
quired for ica-independent biofilm formation.
SigB activity is necessary for biofilm formation. A func-
tional RsbU protein is known to be required for full activity of
SigB (27, 56). To determine if the phenotypes observed in the
rsbU::Tn5 strain were due to a loss of SigB activity, a sigB
deletion was generated using the pKOR1 plasmid (3). Agar
plate phenotypes of the sigB mutant, such as hemolysis, pro-
teolysis, and carotenoid production, were indistinguishable
from the rsbU::Tn5 strain (data not shown). To assess SigB
activity, we utilized the asp23 promoter, which is known to be
exclusively controlled by SigB (27). An asp23 promoter fusion
plasmid (pAH12) was transformed into strains SH1000 (sigB)
and AH1012 (sigB). The sigB mutant showed the expected
loss of asp23-dependent transcription (Fig. 2), indicating that
SigB was not functional. As anticipated, the asp23 promoter
was also not induced in the rsbU::Tn5 mutant (data not
shown).
To examine biofilm phenotypes, strains SH1000 (sigB),
AH528 (rsbU::Tn5), and AH1012 (sigB) were compared in
microtiter assays. Again, the rsbU::Tn5 and sigB mutant
strains showed similar defects in biofilm formation (Fig. 1A).
For a more rigorous examination of biofilm maturation, strains
SH1000 and AH1012 were transformed with the Tet-inducible
GFP plasmid pALC2084 (4), and the strains were grown in a
once-through flow cell system as described previously (11). The
biofilms were examined by CLSM, and similar to previously
reported results (11), SH1000 formed a robust biofilm	20 m
thick after 4 days of growth (Fig. 3A). Consistent with the
microtiter assay, the sigB mutant was defective in flow cell
biofilm formation (Fig. 3B).
To verify the phenotypes of the constructed sigB mutant, a
complementing plasmid with sigB under the control of the
Tet-inducible promoter, plasmid pALC2109 (4), was trans-
formed into AH1012. By performing dose-response tests, we
determined that 50 ng/ml anhydrotetracycline inducer was op-
timal (Fig. 3C), and this induction level was used to comple-
ment other sigB mutant phenotypes. Levels of carotenoid
production, extracellular protease, and -hemolysin activity all
returned to near-wild-type levels (Table 2). Expression of sigB
from pALC2109 also complemented the asp23 promoter de-
fect in the sigB mutant (Fig. 2). Importantly, the biofilm
phenotype of the sigB mutant was complemented in both
microtiter and flow cell models (Fig. 3C and D). Altogether,
these findings indicate that SigB is essential for S. aureus bio-
film formation and that phenotypes of the rsbU::Tn5 mutant
were due to lack of SigB activity.
The SigB biofilm phenotype is independent of exopolysac-
charide. The PIA is important for biofilm formation in S.
epidermidis and some strains of S. aureus (17, 29). SigB is
known to regulate PIA production, and biofilm phenotypes in
SigB-defective strains have been attributed to altered PIA lev-
els (38, 39, 60, 71). Considering these factors, we measured the
production of PIA in the sigB deletion strain to evaluate
whether PIA levels were linked to the biofilm phenotype. As
positive producers of PIA, we used S. epidermidis strain ATCC
R97-03 (65) and the S. aureus PIA-overproducing strain
MN8m (50). For testing PIA levels, S. aureus strains MN8
(sigB), SH1000 (sigB), and AH1012 (sigB) were used, and
for comparison, ica::tet deletions in both strain backgrounds
were examined as negative controls. PIA dot blot s assays were
performed and quantified on a phosphorimager (Fig. 4). Over-
all, the level of PIA production in S. epidermidis was notably
higher than observed in S. aureus, and this difference in levels
was also observed using immunofluorescence (25). As antici-
pated, the MN8 and SH1000 ica::tet mutants did not produce
detectable levels of PIA. Surprisingly, the AH1012 (sigB)
strain produced slightly higher levels of PIA than the wild-type
SH1000 strain although this difference was not statistically
significant (Fig. 4). These observations indicate that changes in
PIA levels are not likely the source of the biofilm phenotype in
an S. aureus sigB mutant, and they support our recent report
that PIA is not essential to form a biofilm in strain SH1000
(11).
The interconnection of SigB with the agr quorum-sensing
system. Defects in SigB are known to have an impact on the agr
quorum-sensing system in S. aureus. It has been reported that
a sigB mutation results in increased expression from the agr P3
promoter (33), meaning that RNAIII levels should be higher
when SigB is defective. We recently demonstrated that high
RNAIII levels have antibiofilm effects (11), suggesting that the
induction of the agr system in a sigB mutant could explain the
observed biofilm phenotype. To investigate this question, we
transformed a P3agr-mCherry reporter plasmid (pAH8) into
SH1000 (sigB) and AH1012 (sigB) and compared P3 expres-
sion levels. At 8 h of growth in TSB, the relative levels of the
P3 promoter were sixfold higher in the SigB-defective strains
(Fig. 5A). As further verification, levels of the RNAIII mRNA
transcript were evaluated using qRT-PCR. A comparison of
SH1000 to AH1012 showed that RNAIII levels increased 11.8-
fold in the sigB mutant (Fig. 5B), supporting the agr P3
promoter fusion results. In a similar qRT-PCR experiment,
RNAIII levels increased nearly 10-fold in the rsbU::Tn5 mutant
(AH528) versus SH1000 (data not shown). These observations
verify previous reports and implicate high levels of RNAIII
FIG. 2. Confirmation of the constructed sigB mutant. Plasmid
pAH12 (Pasp23-mCherry) was used to measure SigB activity from the
asp23 promoter in strains SH1000 (sigB) and AH1012 (sigB). Flu-
orescence readings for the mCherry reporter were taken after 20 h of
growth of cells. For complementation, strain AH1012 (with pAH12)
was transformed with plasmid pALC2109 (Ptet-sigB), and sigB expres-
sion from the tet promoter was induced with 50 ng/ml anhydrotetra-
cycline.
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expression as contributors to the biofilm phenotype in SigB-
defective strains.
To test the RNAIII overproduction hypothesis, a sigB agr
double mutant was constructed and examined for biofilm mat-
FIG. 3. Biofilm phenotypes of the sigB mutant. For flow cells, strains SH1000 (sigB) (A) and AH1012 (sigB) (B) were transformed with
plasmid pALC2084 (induced with 20 ng/ml anhydrotetracycline) to image biofilms with GFP. Biofilms were grown for 4 days in a once-through
flow cell setup, and a z-series of images was taken by CLSM and reconstructed with Volocity software. Each side of a grid square is 20 m in the
image reconstruction. For complementation of the sigB mutant, strain AH1012 was transformed with plasmid pALC2109. Complementation was
assessed with microtiter (C) and flow cell (D) biofilm assays. In the microtiter biofilm, levels of uninduced and induced (50 ng/ml anhydrotetra-
cycline) sigB expression were compared. For the flow cell, a biofilm of strain AH1012 with the sigB expression plasmid pALC2109 (induced with
50 ng/ml anhydrotetracycline) was grown and poststained with Syto9.
TABLE 2. Phenotypes
Strain/plasmid
Hemolysis
(-hemolytic
titer)a
Protease
activity
(%)b
Carotenoid
production
(A450)c
SH1000/pALC2073 110 100 0.60
AH1012/pALC2073 477 1,360 0.07
AH1012/pALC2109d 31 124 0.44
LAC/pALC2073 257 100 0.30
AH1096/pALC2073 1,990 1,050 0.08
AH1096/pALC2109d 57 67 0.36
a Hemolytic titers were calculated from rabbit blood cell lysis as described in
Materials and Methods.
b Protease activity in cell-free supernatants was measured with Azocoll reagent
as described in Materials and Methods. Supernatants of wild-type strains with
control vector pALC2073 were set to 100%.
c Carotenoid production was monitored in methanol extractions of S. aureus
samples at wavelengths of 450 and 470 nm although only one value is reported.
d Complementation with pALC2109 was performed with 50 ng/l anhydrotet-
racycline to induce sigB gene expression.
FIG. 4. PIA production in sigB mutants. Quantitative dot blot s
analysis was performed with anti-PIA antiserum. S. epidermidis R97-03
was used as a positive control producer. For S. aureus, MN8m was used
as a positive control, and a ica mutation served as a negative control
for the MN8, SH1000, and LAC genetic backgrounds. For testing, dot
blot S assays were performed on strains SH1000 (wild-type [WT]),
AH1012 (SH1000 sigB), LAC, and AH1096 (LAC sigB), along with
the indicated controls. The dot blot s results were quantitated with
ImageGauge software (Fuji) and plotted relative to S. epidermidis
R97-03 (S. epi). P values of 
0.05 as calculated by a Student’s t test
were considered statistically significant.
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uration in both microtiter and flow cell formats. In microtiter
plates, introduction of the agr mutation restored biofilm for-
mation compared to the sigB single mutant (Fig. 1A). In flow
cells, a similar enhancement in biofilm formation was observed
(Fig. 5C). For quantitative flow cell assessment, COMSTAT
analysis indicated that the sigB agr double mutant biofilm
had 80% of the biomass of the wild-type strain. In summary,
our findings indicate that the sigB mutant biofilm phenotype
is primarily due to the enhanced activity of the agr system.
Increased protease activity contributes to the sigB mutant
biofilm phenotype. When agr RNAIII levels are high, S. aureus
has increased extracellular protease activity. We recently dem-
onstrated that these increased protease levels have antibiofilm
effects (11). Considering that the sigB mutation leads to a
dramatic increase in RNAIII levels, we reasoned that higher
protease levels could contribute to the biofilm phenotype. To
address this question, the serine protease inhibitor PMSF was
incubated with strains SH1000 (sigB), SH1002 (sarA::Kan),
AH528 (rsbU::Tn5), and AH1012 (sigB). The addition of 400
M PMSF reversed the biofilm phenotype of the rsbU::Tn5
and sigB mutants (Fig. 6) but did not alter the phenotype of
the sarA::Kan mutant. The 400 M level of PMSF did not
affect growth of the strains, but higher PMSF levels were toxic
(data not shown). The solvent used for the PMSF experiment,
2% DMSO, had a minimal effect on biofilm formation. In
repeated experiments, we have also found that general pro-
tease inhibitor 2-macroglobulin could repair the biofilm phe-
notype of SigB-defective strains (data not shown), supporting
the PMSF results. Collectively, these observations implicate
protease activity as a contributor to the sigB mutant biofilm
phenotype.
Inactivation of Aur and Spl proteases restores biofilm for-
mation in a sigB mutant. S. aureus secretes at least 10 extra-
cellular proteases (23). These include the metalloprotease
aureolysin (Aur), V8 (SspA), the six Spl serine proteases, and
the cysteine proteases staphopain A (ScpA) and staphopain B
(SspB). These proteases are encoded in four separate tran-
scripts (aur, sspABC, scpAB, and splABCDEF), and each of
these transcripts is upregulated in a SigB-defective strain (8).
Based on our PMSF findings, we began inactivating protease
genes in the sigB mutant strain AH1012. Introduction of a
individual aur, splABCDEF::Erm, or sspA::Erm mutation
did not restore biofilm formation in AH1012 (data not shown).
However, simultaneous deletion of both the aur and spl loci in
a sigB mutant restored biofilm capacity in the microtiter assay
to wild-type levels (Fig. 7A). The agr system is still functional
in the aur spl mutants (11; also data not shown), indicating that
the effect is not due to secondary mutations in agr. For a more
careful examination of the biofilm phenotype, the GFP plas-
mid pALC2084 was introduced into strains SH1000 (sigB),
AH1012 (sigB), AH750 (aur spl::Erm), and AH1136
(sigB aur spl::Erm). The strains were grown in flow cells
for 4 days and visualized each day by CLSM. As anticipated
FIG. 5. Interconnection between the SigB and agr regulatory systems. (A) Effect of the sigB mutation on agr expression. Plasmid pAH8
(P3agr-mCherry) was used to monitor agr activity in strains SH1000 (sigB
) and AH1012 (sigB). Fluorescence readings for the mCherry reporter
were taken after 8 h of growth in TSB. For complementation, strain AH1012 (with pAH8) was transformed with plasmid pALC2109 (Ptet-sigB),
and sigB expression was induced with 50 ng/ml anhydrotetracycline. (B) Analysis of RNAIII levels with quantitative RT-PCR using strains SH1000,
AH1012, and AH1012 with complementation plasmid pALC2109. RNAIII levels are relative to 16S RNA control transcript. (C) Flow cell biofilm
of strain AH1106 (sigB agr). Flow cell biofilms were grown for 4 days in a once-through setup, and cells were visualized with CLSM using GFP
labeling with plasmid pALC2084 (induced with 20 ng/ml anhydrotetracycline). Each side of a grid square is 20 m in the CLSM image
reconstruction.
FIG. 6. Effect of PMSF on biofilm formation in a sarA mutant and
SigB-defective strains. Microtiter biofilm assays were performed with
SH1000 (sarA sigB), SH1002 (sarA::Kan), AH528 (rsbU::Tn5), and
AH1012 (sigB). Biofilms were grown with TSB alone, 2% DMSO, or
400 M PMSF dissolved in DMSO. Biofilm quantitation is plotted
relative to the OD595 of SH1000 biofilms.
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based on our previous study (11), strains SH1000 and AH750
were robust biofilm formers. In accordance with the microtiter
assay results, introduction of the aur and spl protease knock-
outs restored biofilm capacity to the sigB mutant (Fig. 7B).
Altogether, these observations provide evidence that upregu-
lation of the extracellular proteases in SigB-defective strains
contributes to the biofilm phenotype.
Comparisons to a CA-MRSA USA300 strain. In recent
years, the CA-MRSA USA300 strain lineage has been identi-
fied as the dominant cause of S. aureus infections in many
community and hospital settings (22, 44, 59, 64). To determine
whether our observed phenotypes in the SH1000 genetic back-
ground were consistent in a clinically relevant strain, a sigB
mutant was constructed in isolate LAC (72). The agar plate
phenotypes of the LAC strain versus its sigB mutation (strain
AH1096) were similar to those in the SH1000 genetic back-
ground. Quantitative tests supported this observation as strain
AH1096 showed a dramatic reduction in carotenoid produc-
tion but increased hemolysis and proteolytic activity (Table 2).
Strain AH1096 was transformed with the sigB expression plas-
mid pALC2109, and the plasmid complemented the pheno-
types, indicating that the constructed strain did not have sec-
ondary defects. To confirm that SigB was not active in strain
AH1096, a Pasp23-mCherry promoter fusion plasmid (pAH6)
was transformed and tested in strains LAC and AH1096.
Again, similar to result in the SH1000 background, the asp23
promoter did not activate in AH1096 under stationary phase
conditions (Fig. 8A). RNAIII production was also monitored
using a P3agr-mCherry promoter fusion plasmid (pAH1). The
levels rose twofold in the sigB mutant (Fig. 8B), but the relative
increase was not as high as that observed in the SH1000 back-
ground (Fig. 5A). The natural level of RNAIII expression in LAC
is known to be higher than in methicillin-susceptible S. aureus
strains and other MRSA isolates (52, 73).
The LAC strain has not been characterized in models of
biofilm formation. We were unable to grow biofilms in micro-
titer plates, but LAC was a robust biofilm former in the flow
cell apparatus. To monitor flow cell biofilms, the LAC (sigB)
and AH1096 (sigB) strains were transformed with the GFP-
expressing plasmid pALC2084 and grown for 4 days. Through
visualization of the biofilms with CLSM, the sigB mutation
introduced a striking biofilm phenotype compared to the wild-
type LAC (Fig. 8C and D). Notably, introduction of the sigB-
expressing plasmid complemented the biofilm phenotype (Fig.
8E), demonstrating that the phenotype was due to loss of SigB
activity.
To investigate the interconnection between the SigB and agr
system in the LAC background, an agr mutation was intro-
duced into strains LAC and AH1096, resulting in new strains
AH1203 (agr) and AH1204 (sigB agr), respectively. As
anticipated, the LAC agr mutant (AH1203) was a proficient
biofilm former (Fig. 8F). Similar to the result with SH1000,
introduction of an agr mutation into AH1096 restored biofilm
capacity (Fig. 8G). While the sigB agr double mutant biofilm
was as thick as the LAC wild-type biofilm and appeared normal
in CLSM image reconstructions (Fig. 8G), closer examination
indicated that the biofilm of the double mutant was porous.
COMSTAT analysis showed that the sigB agr double mu-
tant had 50% of the biofilm biomass of the LAC wild-type
strain, which is lower than the 80% recovery observed in the
SH1000 genetic background (Fig. 5C).
To further compare LAC with SH1000, the ica::tet deletion
was moved to LAC, generating strain AH1308. Through quan-
titative dot blot s analysis, the PIA production profile in LAC
was determined to be similar to that of SH1000, with the
ica::tet mutant yielding undetectable levels of PIA and the
sigB mutation resulting in minor PIA enhancement (Fig. 4).
Notably, the LAC ica::tet mutant displayed no defect in the
flow cell biofilm model compared to wild-type (data not
shown). Overall, the sigB mutant phenotypes of the LAC
strain mirrored those of the SH1000 strain, suggesting that
both SigB regulatory systems function in a similar manner.
Murein hydrolases as a protease target. Thus far, we linked
the sigB mutant biofilm phenotype to the upregulation of the
agr system and increased extracellular protease activity. Going
forward, what are the proteases cleaving that disables the abil-
ity to develop a biofilm? While there are numerous target
possibilities, several S. aureus studies have linked defects in
murein hydrolase activity to a biofilm phenotype (9, 32, 61, 68).
FIG. 7. Effect of protease mutations on biofilm formation in a
sigB mutant. (A) Microtiter biofilm assays of SH1000, AH1012
(sigB), AH750 (aur spl), and AH1136 (sigB aur spl) strains.
(B) Flow cell biofilm of strain AH1136. Flow cell biofilms were grown
for 4 days in a once-through setup, and cells were visualized with
CLSM using GFP labeling with plasmid pALC2084 (induced with 20
ng/ml anhydrotetracycline). Each side of a grid square is 20 m in the
CLSM image reconstruction.
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We reasoned that the increase in protease activity in the sigB
mutant could be impacting the function of murein hydrolases,
paralleling observations made in Bacillus subtilis (36, 41). To
investigate this hypothesis, we prepared cell-free supernatants
of wild-type and sigB mutants of strains SH1000 and LAC
and performed protease zymography (Fig. 9A) and autolysin
zymography (Fig. 9B) on these samples. As anticipated, the
sigB mutants of both the SH1000 and LAC strains displayed
increased protease activity versus the parental wild-type strains
(Fig. 9A, lane 2 versus lane 3 for SH1000 and lane 5 versus lane
6 for LAC). The protease enhancement was more significant
for SH1000 than LAC, supporting our observations from pro-
tease assays with Azocoll reagent (Table 2). When the sigB-
complementing plasmid pALC2109 was provided, protease ac-
tivity decreased (Fig. 9A, lanes 4 and 7). Induction of sigB
expression in the LAC background appeared to slightly over-
compensate and repress protease production beyond wild-type
levels (Fig. 9A, compare lanes 5 and 7), similar to what we
FIG. 8. LAC wild-type and sigB mutant phenotypes. (A) Plasmid pAH6 (Pasp23-mCherry) was used to measure SigB activity from the asp23
promoter in strains LAC (sigB) and AH1096 (sigB). Fluorescence readings for the mCherry reporter were taken after 20 h of growth of cells.
(B) Plasmid pAH1 (P3agr-mCherry) was used to monitor agr activity in LAC and AH1096 after 8 h of growth in TSB. (C to G) CLSM
reconstructions of flow cell biofilms grown for 4 days. Strains LAC, AH1096, AH1203, and AH1204 were visualized by CLSM using GFP labeling
with plasmid pALC2084 (induced with 20 ng/ml anhydrotetracycline). For complementation assessment (E), a biofilm of strain AH1096 with the
sigB expression plasmid pALC2109 (induced with 50 ng/ml anhydrotetracycline) was grown in the flow cell and poststained with Syto9. Each side
of a grid square is 20 m in the CLSM image reconstruction.
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observed using Azocoll reagent (Table 2). To further investi-
gate the protease connection, we utilized a double knockout of
the aur spl::Erm loci, which we previously reported to have
low extracellular protease activity (11). When these protease
knockouts were moved to a sigB mutant (strain AH1136),
extracellular protease activity was not detectable by zymogra-
phy in the triple mutant (Fig. 9A, lane 1).
To assess the function of murein hydrolases, the same sam-
ples were tested in autolysin zymography using M. luteus cells
as a substrate (Fig. 9B). In the sigB mutants, we observed a
significant increase in the activity of two lower-molecular-mass
murein hydrolases in the 30- to 37-kDa size range (Fig. 9B,
lanes 3 and 6). In the SH1000 sigB mutant (AH1012), a
corresponding decrease in the activity of a 50-kDa protein was
apparent, but this decrease was not significant in the LAC
sigB mutant (AH1096). Thus, the lack of SigB activity altered
the autolysin profile, resulting in an enhancement in low-mo-
lecular-mass murein hydrolases. When sigB was provided on a
plasmid, the activity trend changed back to the wild-type pro-
file, demonstrating complementation of the phenotype. Impor-
tantly, when the Aur and Spl proteases were deleted in the
AH1012 sigB mutant, the murein hydrolase profile also re-
turned to the wild-type trend, suggesting that the changes were
a direct reflection of the extracellular protease activity level.
Altogether, the sigB mutants display altered murein hydro-
lase profiles, which may be a contributing factor to the biofilm
phenotype in these mutants.
DISCUSSION
Through random mutagenesis, we identified the SigB system
as an important biofilm regulator under ica-independent con-
ditions. We linked the SigB biofilm phenotype to the overex-
pression of agr RNAIII and demonstrated that increased pro-
tease activity was a contributor to the biofilm phenotype.
Finally, we observed that the SigB biofilm phenotypes were
consistent in a clinical CA-MRSA USA300 isolate.
Our findings clarify the mixed reports on the role of SigB in
biofilm maturation (12, 49, 54, 60, 70). Under ica-independent
conditions, our results demonstrate that SigB is essential for
biofilm formation in multiple strain backgrounds. Valle et al.
reported that a sigB mutant of S. aureus strain 15981 formed a
biofilm (70), but it was later observed that this strain has an agr
mutation (67). As we demonstrated in this report, when the agr
system is defective, the SigB biofilm phenotype is masked,
perhaps explaining the observed phenotype in strain 15981.
Mutations in the ica locus of strain 15981 are also known to
alter biofilm development (71), suggesting that this strain
forms an ica-dependent biofilm, which may be another expla-
nation for the observation that 15981 sigB mutants retain bio-
film capacity.
Our findings implicate the elevated protease levels in a sigB
mutant as important contributors to the biofilm phenotype.
Considering the results with sigB agr double mutants, the al-
tered protease regulation is likely a result of high RNAIII
expression and not direct regulation of the protease genes by
SigB. These findings parallel our recent report that demon-
strates that extracellular proteases are required for biofilm
dispersal (11). Putting these observations together, we propose
that regulatory mutations resulting in high protease levels will
block S. aureus biofilm attachment and maturation under ica-
independent conditions.
Our experiments with the sarA mutant indicate that the
biofilm defect results from a different mechanism than that
observed for SigB. The protease inhibitor PMSF recovered the
sigB mutant defect but did not alter an sarA mutant biofilm,
suggesting that the sarA phenotype is more complex. It is
important to note that lower sarA expression could have some
contribution to the sigB biofilm phenotype. In a sigB agr double
mutant background, the biofilm capacity recovered to approx-
imately 80% of the wild-type level in strain SH1000, and the
recovery was even lower in strain LAC. SigB is known to be
required for full sarA expression (8, 57), and the lower levels of
sarA could explain the reduced biomass in the double mutant
biofilm.
To compare our results with a clinical isolate, we examined
biofilm maturation and the role of SigB in the CA-MRSA
FIG. 9. Protease and autolysin zymography in sigB mutants. Gel
images are black-white inverted to aid visualization. (A) Extracellular
protease zymography using 8% SDS-PAGE supplemented with 0.2%
gelatin as a substrate. (B) Autolysin zymography using 8% SDS-PAGE
supplemented with 0.2% M. luteus cells as a substrate. Lanes are
identical in both protease and autolysin gels. Labels at the top of panel
A indicate the genetic background. The presence or absence of SigB is
indicated as follows: , chromosomal sigB; C, plasmid-encoded sigB. Lane
1, AH1136 (sigB aur spl::Erm); lane 2, SH1000 with pALC2073;
lane 3, AH1012 with pALC2073; lane 4, AH1012 with pALC2109; lane
5, LAC with pALC2073; lane 6, AH1096 with pALC2073; lane 7,
AH1096 with pALC2109. Expression of sigB from plasmid pALC2109
was induced with 50 ng/ml anhydrotetracycline.
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strain LAC. USA300 strains are emerging as causative agents
of biofilm-related infections (31), and strain LAC is a repre-
sentative isolate that has recently been the subject of several
studies (13, 72, 73). In our hands, LAC attached poorly to
microtiter plates, and thus we performed all experiments under
flow cell conditions. We speculate that extracellular enzymes
and the agr autoinducing peptide are washed away in the flow
cells, enabling the LAC strain to attach and develop a biofilm.
We have experienced similar microtiter problems with other S.
aureus strains that are also alleviated using flow cell conditions
(data not shown). Importantly, the extracellular enzyme and
biofilm phenotypes of the LAC sigB mutant were similar to
those of SH1000, indicating that they are not a strain-specific
issue and are consistent in clinical isolates. Although prelimi-
nary, these results suggest that the SigB regulatory system
functions in an identical manner in strains SH1000 and LAC.
While we have linked the SigB biofilm phenotype to extra-
cellular proteases, the target of the proteases is still unknown.
A theme emerging from numerous S. aureus biofilm studies is
that murein hydrolases are important for biofilm maturation
(9, 61, 68). This link is not limited to S. aureus as similar
observations have been made in many gram-positive organ-
isms, including S. epidermidis (32), Streptococcus mutans (1),
Enterococcus faecalis (66), and Lactococcus lactis (51). We
hypothesized that murein hydrolase function could be modu-
lated by the extracellular protease enzymes, contributing to the
observed sigB mutant biofilm phenotypes. In support of this
argument, S. aureus and B. subtilis murein hydrolases show
susceptibility to proteolytic degradation (41, 74). In S. aureus
sigB mutants, the murein hydrolase profile changed, resulting
in increased levels of low-molecular-weight activities. When
extracellular proteases were inactivated in combination with
the sigB mutation, the murein hydrolase profile returned to the
wild-type trend, supporting a link between extracellular pro-
tease activity and murein hydrolase function. It is possible that
the increased protease levels cleaved a high-molecular-weight
murein hydrolase to a smaller size or, alternatively, triggered
the activation of a dormant enzyme. Considering the numerous
secreted protease and murein hydrolase activities, how all the
cross-talk occurs at a mechanistic level and further interfaces
with biofilm maturation remains an open question. While the
autolytic profiles have changed in sigB mutants, the corre-
sponding effect on cell lysis and DNA release are not known
and could also be a contributor to the biofilm phenotype.
Altogether, our findings demonstrate that the SigB system is
essential for ica-independent biofilm formation in S. aureus.
The results of the mutant epistasis studies suggest that SigB is
operating upstream of the agr quorum sensing, presumably to
respond to environmental cues. Based on our observations and
published reports, stress conditions that induce the SigB cas-
cade will favor biofilm formation due to lower agr RNAIII
levels, resulting in reduced extracellular protease activity. Con-
versely, conditions that inhibit SigB activity will increase
RNAIII expression and have antibiofilm effects. Thus, condi-
tions that favor low SigB activity will block biofilm maturation
although the environmental or host factors that lead to SigB
inhibition remain to be defined. It is possible that SigB inhibi-
tion will also disperse an established biofilm. In support of this
proposal, repression of SigB in established S. epidermidis bio-
films led to a pronounced dispersal event (34), suggesting that
a similar mechanism may occur in S. aureus. Further insight
into the SigB regulatory mechanism would improve our under-
standing of biofilm maturation and dispersal pathways.
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